The next-generation cereblon-targeting agent mezigdomide shows early signs of clinical efficacy in patients with heavily pretreated multiple myeloma, highlighting the potential of rational drug design to improve the potency of immunomodulatory therapies that function as molecular glues.

©2023 American Association for Cancer Research
2023
American Association for Cancer Research
You do not currently have access to this content.